Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(43%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
29%
Ph not_applicable
1
14%
Ph phase_2
4
57%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(6)
Completed(1)

Detailed Status

Not yet recruiting3
Active, not recruiting2
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
N/A1 (14.3%)

Trials by Status

active_not_recruiting229%
completed114%
not_yet_recruiting343%
recruiting114%

Recent Activity

3 active trials
Showing 5 of 7
active_not_recruitingphase_2

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

NCT06594146
not_yet_recruitingnot_applicable

A Single-center Study of CM313 in Patients With Pemphigus

NCT06904040
completedphase_2

A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

NCT05694767
not_yet_recruitingphase_2

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

NCT06791772
active_not_recruitingphase_2

A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

NCT06199089
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06594146Phase 2

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Active Not Recruiting
NCT06904040Not Applicable

A Single-center Study of CM313 in Patients With Pemphigus

Not Yet Recruiting
NCT05694767Phase 2

A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Completed
NCT06791772Phase 2

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

Not Yet Recruiting
NCT06199089Phase 2

A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Active Not Recruiting
NCT06285227Phase 1

Study of CM313 in Healthy Subjects

Recruiting
NCT06126237Phase 1

A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma

Not Yet Recruiting

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7